Peer-reviewed veterinary case report
High chemokine CXCL7 linked to canine transmissible venereal tumor
By Chiang, Hsin-Chien et al.·Published in BMC veterinary research·2012·School of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Overexpression of chemokine ligand 7 is associated with the progression of canine transmissible venereal tumor.
- Species:
- dog
Plain-English summary
A study found that a specific protein called CXCL7 is linked to the growth of a type of tumor in dogs known as transmissible venereal tumor (TVT). In dogs with the progressive phase of this tumor, CXCL7 levels were high, while they decreased in the regressive phase when the tumor shrinks. Researchers discovered that a protein called IL-6 can lower CXCL7 levels, which may help control tumor growth. This suggests that targeting CXCL7 could be a potential treatment approach for dogs with TVT.
People also search for: dog tumor treatment · transmissible venereal tumor in dogs · IL-6 and cancer in dogs
Abstract
BACKGROUND: Chemokines play multiple roles in the development and progression in a variety of tumors. Chemokine (C-X-C motif) ligand 7 (CXCL7) has been found associated with pro-inflammatory responses, but its role in cancer growth remains unclear. Our previous study showed that R phase tumor infiltrating lymphocytes (TILs) produced large amounts of interleukin (IL)-6 which antagonized transforming growth factor (TGF)-β derived from CTVT to diminish the immune-suppressive microenvironment. Now we intend to determine the expression pattern of CXCL7 and the role of IL-6/TGF-β in CXCL7 induction during spontaneous progressive (P) and regressive (R) phases in canine transmissible venereal tumor (CTVT). RESULTS: We have demonstrated that CXCL7 expressed at high level in P phase and down-regulated in R phase by western blot and real-time PCR. This suggested that CXCL7 expression was negatively correlated with the tumor growth. Co-culturing TILs with CTVT cells was found to reduce CXCL7 expression, while adding IL-6 blocking antibody reversed it. Moreover, in P phase CTVT, while IL-1β and TGF-β had no obvious effect on CXCL7 expression, IL-6 was found significantly to reduce CXCL7 expression in a dose-dependent manner. The mRNA expression results of CXCL7 receptor, CXCR2, further confirmed the effects of IL-6 concentration on the CXCL7 expression. CONCLUSION: CXCL7 overexpression might be associated with the progressive growth of CTVT. The results shown here also suggest the role of CXCL7 in cancer development and the potential as the anti-cancer therapeutic target.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23136963/